Cambridge-based Agios and Celgene, a global biopharmaceutical company, are forming a global strategic collaboration focused on targeting cancer metabolism. The goal of the collaboration is to discover, develop, and deliver disease-altering therapies in oncology based on the science of Agiosí cancer metabolism research platform, the two companies said in a press release.
Under the agreement, New Jersey-based Celgene "receives an initial period of exclusivity during which it has the option to develop any drugs resulting from the Agios cancer metabolism research platform," the press release said. "In addition, Celgene may extend this exclusivity period through additional funding. If successful, Agios would receive substantial regulatory, clinical, and commercial milestones."